Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Short Term Outcome of SGLT2 Inhibitors on Patients Who Undergo Cardiac Surgery in Perioperative Period

ID
Name
SGLT2 inhibitors
Description
The expanded use of SGLT2 inhibitors motivates us to assess the role of SGLT2 inhibitors in perioperative period on patients who will undergo cardiac surgery in Assiut University.
Trial arms
Trial start
2024-05-01
Estimated PCD
2025-04-01
Trial end
2025-10-01
Status
Not yet recruiting
Treatment
SGLT2 inhibitor
Dapagliflozin 10 mg or Empagliflozin 25mg
Arms:
SGLT2 group
Other names:
Dapagliflozin and Empagliflozin
Size
100
Primary endpoint
Difference of cardiac function by speckle tracing between patients who will receive SGLT2 and patients who not.
six months
Eligibility criteria
Inclusion Criteria: 1. All subjects with coronary artery disease or valvular heart disease referred to cardiac surgery Exclusion Criteria: 1. Congenital heart disease. 2. Cardiomyopathy (EF\>40%). 3. Sever renal impairment (eGFR\>30). 4. COPD. 5. Marked obesity (BMI\<35). 6. Previous cardiac surgery.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 100, 'type': 'ESTIMATED'}}
Updated at
2024-03-22

1 organization

1 product

1 indication

Organization
Assiut University
Product
SGLT2 inhibitor
Indication
Perioperative Complication